Xin Lang Cai Jing·2026-02-09 01:12Core Viewpoint - The approval of ICP-538 by the National Medical Products Administration (NMPA) marks a significant milestone for the company as it is the first VAV1 molecular glue degrader developed in China and the second globally to enter clinical research [1] Group 1: Product Development - ICP-538 is a novel oral, highly efficient, and selectively targeted VAV1 molecular glue degrader [1] - VAV1 is a critical protein downstream of T cell and B cell receptors, which is essential for developing treatments for various difficult-to-treat autoimmune diseases [1] Group 2: Market Context - Currently, there are no approved VAV1-targeted drugs available in the global market [1] - The potential applications of ICP-538 include treatment for inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and multiple sclerosis (MS) [1]